HK Movers | RemeGen Shares Plunge 21% as It Partners with Vor Biopharma for Global Expansion of Telitacicept

RemeGen shares plunged 20.9% in morning trading.

RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China.

This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&D risks.

The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.